These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8865481)

  • 1. Management of stage T1a prostate cancer.
    Lowe BA
    Semin Urol Oncol; 1996 Aug; 14(3):178-82. PubMed ID: 8865481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging of incidentally detected prostate cancer: role of repeat resection, prostate-specific antigen, needle biopsy, and imaging.
    Griebling TL; Williams RD
    Semin Urol Oncol; 1996 Aug; 14(3):156-64. PubMed ID: 8865478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Descazeaud A; Peyromaure M; Salin A; Amsellem-Ouazana D; Flam T; Viellefond A; Debré B; Zerbib M
    Eur Urol; 2008 Feb; 53(2):355-61. PubMed ID: 17611015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Joniau S
    Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Scattoni V
    Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
    [No Abstract]   [Full Text] [Related]  

  • 7. Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?
    Epstein JI
    Semin Urol Oncol; 1996 Aug; 14(3):165-73. PubMed ID: 8865479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification].
    Leisinger HJ
    Ann Urol (Paris); 1994; 28(4):229-34. PubMed ID: 7979213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
    Jones JS; Follis HW; Johnson JR
    Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies.
    Philip J; Dutta Roy S; Scally J; Foster CS; Javlé P
    Prostate; 2005 Jul; 64(2):200-2. PubMed ID: 15712218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
    Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
    BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.